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 2 
Abstract 43 
 44 
Background: Several Streptococcus pneumoniae proteins play a role in pathogenesis 45 
and are being investigated as vaccine targets.  It is largely unknown whether naturally-46 
acquired antibodies reduce the risk of colonization with strains expressing a particular 47 
antigenic variant. 48 
Methods: Serum IgG titers to 28 pneumococcal protein antigens were measured among 49 
242 individuals, aged < 6 months - 78 years in Native American communities between 50 
2007-2009. Nasopharyngeal swabs were collected at least 30 days after serum 51 
collection, and the protein antigen variant in each pneumococcal isolate was determined 52 
using genomic data.  We assessed the association between preexisting variant-specific 53 
antibody titers and subsequent carriage of pneumococcus expressing a particular 54 
antigen variant. 55 
Results:  Antibody titers often increased across pediatric groups before decreasing 56 
among adults.  PspA and StkP IgG titers decreased from <6 months to 6-12 months 57 
(p<0.01).  Individuals with low titers against Group 3 PspC variants were more likely to 58 
be colonized with pneumococci expressing those variants.  For other antigens, variant-59 
specific IgG titers do not predict colonization with pneumococci expressing particular 60 
variants. 61 
Conclusion: We observed an inverse association between variant-specific antibody 62 
concentration and homologous pneumococcal colonization for only one protein. Further 63 
assessment of antibody repertoires may elucidate the nature of anti-pneumococcal 64 
antibody-mediated mucosal immunity while informing future vaccine development.  65 
 66 
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 3 
Introduction 70 
Current pneumococcal conjugate vaccines have significantly reduced invasive 71 
disease caused by the included Streptococcus pneumoniae (pneumococcal) serotypes. 72 
However, the currently licensed vaccines, PCV-10 and PCV-13, target only 10 or 13 of 73 
the ~90 recognized pneumococcal capsular serotypes. In addition to incomplete 74 
coverage of disease-causing types, significant disadvantages of capsular vaccines 75 
include their production cost, production complexity, and serotype replacement.  While 76 
PCV formulations are still an attractive vaccine approach, these limitations have 77 
motivated pursuit of pneumococcal protein antigens as vaccine candidates. Protein-78 
based vaccines would, in theory, generate robust antibody responses, be efficacious in 79 
young children, and may decrease carriage (1). 80 
Pneumococcal surface protein A (PspA), PspC, pilus (RrgA/B/C), pneumolysin 81 
(Ply) and neuraminidase (NanA) are among the pneumococcal proteins being 82 
investigated for use in vaccine formulations (1).  Studies suggest that in some cases 83 
combinations of these proteins may elicit better protection than any of the proteins 84 
themselves (1,2).  In humans, antibodies to pneumococcal proteins can be detected 85 
during colonization and natural infection, providing protection from subsequent 86 
colonization and invasive disease (3–8).  Virolainen et al. showed that among children 87 
with invasive pneumococcal infections, those with lowest antibody titers to PspA were 88 
infected most frequently with pneumococci (9).  However, animal data show that while 89 
antiprotein antibodies are correlated with protection against subsequent challenge, the 90 
mechanism of protection is not necessarily antibody mediated, suggesting antibody 91 
levels may correlate with degree of immune response but not necessarily exclusively 92 
mediate protection.  Evidence of variant-specific protection, in which antibodies to a 93 
particular protein antigenic variant correlate with protection against colonization by 94 
homologous pneumococci (i.e. those with that protein variant), would be more strongly 95 
 4 
indicative of antiprotein antibodies’ causal role in protection, as has been observed for 96 
serotype-specific anticapsular antibodies (10,11).  97 
At the same time, such evidence would provide a mechanism to explain the high 98 
level of sequence variation and signs of diversifying selection at these loci.  While these 99 
protein antigens are present in almost all pneumococci, they are also very diverse, and 100 
pneumococcal strains differ considerably in the particular antigenic variants they express 101 
(12).  Two clear examples are the surface associated choline-binding proteins PspA and 102 
PspC.  Both are encoded by polymorphic genes with clear structural variability, which 103 
becomes the basis for their division into 3 PspA families and 11 PspC groups (12,13).  104 
Studies suggest structural differences in these proteins impact the nature and specificity 105 
of the antibody response generated toward them.  For example, family-specific antibody 106 
responses among children exposed to pneumococci possessing family 1 and 2 PspA 107 
variants have been observed (14).  108 
Important uncertainties remain about the biologic function of protein antibodies 109 
and the extent to which their binding and activity are specific to particular variants of 110 
polymorphic antigens. Here, we investigate whether naturally acquired antibodies to 111 
protein antigens reduce the risk of nasopharyngeal acquisition (i.e. colonization) with 112 
strains containing particular variants of diverse proteins such as PspA and PspC.  To 113 
address this question, we used pneumococcal genomic data to identify variants of 21 114 
pneumococcal protein antigens present in S. pneumoniae carriage isolates.  We then 115 
assessed the association between antibody titers and subsequent colonization with S. 116 
pneumoniae strains expressing an antigen recognized by preexisting antibodies. We 117 
posited that individuals who had low antibody titers to a specific protein antigen variant 118 
would be more likely to be colonized with S. pneumoniae expressing that variant.   119 
 120 
Methods  121 
 5 
 122 
Study Population, Serum Collection, and Nasopharyngeal Colonization 123 
 124 
Individuals included in this study were a subset of participants in a larger 125 
prospective, longitudinal, observational cohort study of pneumococcal carriage among 126 
Navajo and White Mountain Apache families described elsewhere (15).  Briefly, 127 
participants living on reservations in the southwest USA were enrolled from March 2006 128 
to March 2008.  Demographic and epidemiological data are provided in Supplementary 129 
Table 1.  Serum and nasopharyngeal (NP) specimens were obtained on the initial visit 130 
after recruitment, and NP samples were collected at each of six follow-up visits at one-131 
month intervals to determine pneumococcal carriage status (16).  We selected 132 
individuals who were negative for carriage at the initial visit, had an available enrollment 133 
serum sample, and subsequently had a pneumococcal isolate detected >30 days after 134 
serum collection. The Navajo Nation, White Mountain Apache tribe and the IRBs of the 135 
Johns Hopkins Bloomberg School of Public Health, the Navajo Nation and the Phoenix 136 
Area IHS approved this study.  Written informed consent was obtained from adult 137 
participants and from caregivers of child participants. Assent was obtained from children 138 
7-17 years. 139 
 140 
Protein Antigen Serology  141 
 142 
Serum IgG to 28 pneumococcal protein antigens were measured using direct 143 
binding electrochemiluminescence-based multiplex assay (MSD, Rockville, MD) (7).  144 
Antibody levels among participants are expressed as a titer relative to the amount in a 145 
reference serum.  The 28 antigens represent 21 pneumococcal proteins and alleles or 146 
structural variants of polymorphic proteins (Table 1).  In particular, antibody titers were 147 
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measured for variants of PcpC, PspA, pilus subunit RrgB, pneumolysin (ply), and 148 
pneumococcal histidine triad D (PhtD).  Four PspC variants, representing four of the 11 149 
recognized major groups (12), were selected based on their prevalence in a 150 
pneumococcal carriage study in Massachusetts, USA (17).  Two variants, var-I and var-151 
II, contain choline-binding domains (CBD), while var-III (Group 7) and var-IV (Group 8) 152 
contain the LPXTG (sortase) motif.  Truncated PspC constructs were designed to 153 
uniquely represent each PspC variant.  Truncation removed the proline-rich and cell wall 154 
anchor motifs, which are highly homologous to those found in PspA (Supplementary 155 
Figure 1).  156 
 157 
Genome Sequencing and Protein Antigen Identification 158 
 159 
Genomic DNA from S. pneumoniae isolates were sequenced on the Illumina 160 
HiSeq to produce paired-end 100 bp reads at >30-fold coverage.  Serotypes were 161 
determined by mapping reads to concatenated CPS locus sequences of 90 162 
pneumococcal serotypes using SRST2 (18,19).  De novo genome assemblies were 163 
generated with Velvet (20) and annotated using Prokka (21).  Pangenome analysis was 164 
conducted with Roary (22) to cluster and abstract protein antigen genes.  The coding 165 
sequence for each protein antigen in the MSD assay was downloaded from KEGG 166 
(http://www.kegg.jp/) and orthologs from S. pneumoniae reference strains were identified 167 
(Table 1).  The MSD index variant, S. pneumoniae reference orthologs, and de novo 168 
assembled protein antigen genes were aligned with PRANK using a codon-aware 169 
algorithm (23).  The diversity of each protein antigen among sequenced isolates was 170 
assessed to classify each antigen as polymorphic or conserved.  Maximum likelihood 171 
phylogenies were inferred from the alignments using RAxML v8.0.0.  For polymorphic 172 
antigens, one reference variant was selected from each monophyletic clade and used to 173 
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construct a protein database for SRST2 (19).  To determine the antigenic profile of each 174 
carried pneumococci, reads were mapped to each variant and the highest scoring match 175 
was reported. 176 
   177 
Statistical Analysis 178 
 179 
To investigate correlation among participants’ anti-protein titers and association 180 
with age, we performed hierarchical clustering of 28 titers using the mclust v5.2 package 181 
in R.  We then assessed the association between titers and subsequent carriage of a 182 
pneumococcus possessing alleles against which the participant had antibodies.  For 183 
each polymorphic protein antigen, log antibody titers were compared among individuals 184 
carrying a pneumococcus with the respective variant.  Statistical significance was 185 
assessed using analysis of variance and Tukey’s HSD.  For the pilus (RrgA/B), which is 186 
present in only a fraction of pneumococci, we assessed anti-pilus titers between 187 
individuals colonized with piliated and non-piliated strains. 188 
 189 
Results 190 
This analysis included 242 participants who had new pneumococcal colonization 191 
>30 days after serum collection (range 30-225 days, median=69).  Individuals ranged in 192 
age from <1 month to 78 years of age, and had 34 pneumococcal serotypes identified in 193 
addition to 4 non-typable isolates (Supplementary Table 2).  For two participants, two 194 
serotypes were identified, and a single serotype was selected for WGS.  Among 195 
participants, 14 carried pneumococci that were PCV-7 vaccine types, and the distribution 196 
of PCV-7 types did not significantly differ by age group (Fisher's Exact, p=0.28). 197 
 198 
Classification of pneumococcal protein antigens 199 
 8 
Phylogenetic analysis identified 11 polymorphic protein antigens and 10 that 200 
were largely conserved.  Table 2 lists the variant frequencies for the 21 protein antigens.  201 
In some cases, the protein antigen variant was unable to be assigned; therefore, counts 202 
for some antigens do not total 242. We measured antibody titers to multiple variants of 203 
three proteins with polymorphisms (PspC, PspA, and RrgB).  For the remaining 10 204 
proteins, we measured antibody titers for one variant and compared titers among 205 
individuals with carriage isolates possessing polymorphic variants.  206 
 207 
Protein Antigen Serology 208 
 209 
Participants’ responses to different PspC variants were positively correlated, 210 
(r=0.29-0.90, p<0.05 for all correlations), such that those with high PspC var-I titers also 211 
had high titers to the other PspC variants (Figure 1 and Supplementary Figure 2).  Titers 212 
against two of the three RrgB variants were highly correlated with each other (0.96, 213 
p<0.01), and less correlated with those against Var-III (Figure 1 and Supplemental 214 
Figure 3).  Among other protein antigens, we found significant correlation between 215 
variants of the same antigen (Figure 1).  There was also high correlation among 216 
antigens including PiuA, PiaA, PcsB, Spr2021, PcpA, CbpA, PhtE, and PhtD. 217 
Antibody titers for most proteins increased with age including PspC variants 218 
(Figure 2A), PspA variants (Figure 2B), Ply variants (Figure 2D) and others 219 
(Supplementary Figure 4).  Anti-pilus (RrgA/B) titers did not vary across pediatric ages; 220 
however, adults (18+ years) had significantly higher anti-RrgA/B titers compared to 221 
pediatric participants (<18 years) (p<0.001) (Figure 2C).  For PspA (p<0.01), StkP 222 
(p<0.01) and PhtD  (p<0.01), participants 6-12 months and 12-24 months had lower 223 
titers than <6-month-old participants.  Among most protein antigens, the magnitude of 224 
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titers were comparable, with the exception of PspC var-IV titers that were an order of 225 
magnitude lower across all ages, compared to other PspC variants. 226 
Hierarchical clustering of individual sera by the patterns of scaled antibody titers 227 
identified two clusters. The larger cluster (A) included substantial numbers of participants 228 
from all age groups, while cluster B was comprised largely of participants <5 years of 229 
age (86.8%) (Supplemental Figure 5).  This cluster of pediatric participants had antibody 230 
titers below the population mean for a large proportion of protein antigens, compared to 231 
pediatric participants in cluster A, suggesting this population was either comparatively 232 
unexposed to pneumococcal protein antigens, or unresponsive to them. 233 
 234 
Analysis of individual protein sequence variation and association with antibody titers 235 
 236 
PspC 237 
 238 
Among PspC variants, var-I was the most prevalent (84.1% of carriage isolates) 239 
followed by var-II (12%).  Var-I corresponds to Groups 2, 3 and 6 of PspC proteins 240 
based on sequence identity and structural organization, and var-II corresponds to Group 241 
4 (Table 1) (12).  The low prevalence of other PspC variants largely limited statistical 242 
comparison of anti-PspC titers to var-I and var-II.  As age may mediate pneumococcal 243 
carriage, we first investigated carriage of the PspC var-I by age group and found that it 244 
did not differ significantly between pediatric and adult participants (X2=0.03, p-245 
value=0.87).  Similarly, PspC variants II-IV did not significantly differ by age group.  Anti-246 
PspC titers did not differ significantly by pneumococcal carriage isolate variant for var-II 247 
(p=0.18), var-III (p=0.23), or var-IV (p=0.53) (Figure 3A); however, differences in anti-248 
var-I titers among participants carrying PspC variants approached statistical significance 249 
[F(3)=2.41, p=0.07].  We collapsed non-var-I PspC variants into a single category and 250 
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compared titers between var-I and non-var-I.  We found anti-var-I titers were significantly 251 
lower among individuals who went on to acquire strains possessing var-I [median log 252 
antibody titer 3.20 (var-I) vs. 3.31 (non-var-I) (p=0.019)] (Figure 3B).  This correlation 253 
was found in all age groups but only significant for participants <1 year of age 254 
(Supplementary Figure 6).  In a logistic regression model controlling for age, low var-I 255 
titers were significantly associated with subsequent carriage of a strain carrying the var-I 256 
variant (OR=0.36, 95% CI 0.14-0.81, p= 0.02).  This suggests that low anti-var-I titers 257 
may be positively associated with acquisition of a strain possessing the PspC var-I.   258 
 259 
PspA 260 
 261 
Among pneumococci in this sample, we identified all three families of PspA 262 
variants described by Hollingshead and colleagues (13).  Most isolates (70%) were 263 
family 1 PspA variant (Table 1).  Additionally, 1% of strains (n=3) were a PspA variant 264 
that formed an out-group to Families 1-3.  Anti-PspA antibody titers were assessed 265 
among individuals carrying four PspA variants (Family 1-3 and Unknown).  Among 266 
participants carrying pneumococcal strains with polymorphic PspA variants, anti-PspA 267 
titers for Family 1 and 2 did not significantly differ (p=0.53 and 0.62) (Figure 3C).  268 
Additionally, carriage of PspA variants was not found to vary by age. 269 
 270 
Type 1 Pilus (RrgA-C) 271 
 272 
Using the presence of RrgB as a marker, we found 11% of carriage strains were 273 
piliated (Table 1).  Among piliated strains (n=24), RrgB var-II was most common, 274 
followed closely by the var-III.  Piliated strains were most often serotype 35B (42.9%), 275 
7B (21.4%), or 19A (14.3%).  Carriage of a piliated pneumococcus did not significantly 276 
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differ between pediatric and adult participants (X2=0.49, p=0.49).  Anti-RrgB antibody 277 
titers of var-II and var-I did not significantly differ by carriage variant (p=0.38 and 0.37) 278 
(Figure 3C).  However, we found that anti-RrgB var-III titers were significantly higher 279 
(p<0.001) among participants with subsequent carriage strains possessing var-III RrgB.  280 
This is contrary to what would be expected if higher variant specific titers were protective 281 
against colonization with respective strains.  Anti-RrgA titers also did not significantly 282 
differ among carriage variants  (p= 0.148).  Last, we assessed anti-RrgB titers among 283 
carriage variants, comparing participants carrying piliated and non-piliated strains.  Anti-284 
RrgB titers did not significantly differ among participants subsequently colonized with 285 
piliated or non-piliated strains (Supplemental Figure 7).   286 
 287 
Other polymorphic protein antigens 288 
 289 
For the polymorphic protein antigens NanA, SP0609, SP2194, PhtD, StkP, and 290 
StrH, where antibody titers were measured for only one variant, we compared titers 291 
among participants carrying pneumococci with heterologous antigen variants 292 
(Supplementary Figure 8).  Distribution of NanA variants I-III did not differ between 293 
pediatric and adult participants (p=0.32).  Anti-NanA titers varied among participants 294 
(p=0.08), with var-I titers marginally lower among participants carrying pneumococci with 295 
var-I.  Interestingly, var-I was the least common, present in only 3.0% of carriage 296 
isolates.  No statistically significant differences in anti-protein antibody titers were 297 
observed among the remaining polymorphic proteins.  Additionally, with the exception of 298 
SP0609, for which the var-I was more prevalent among pediatric participants (p=0.001), 299 
protein antigen variant frequencies did not differ by age group. 300 
 301 
Discussion 302 
 12 
Protein-based vaccines aim to further reduce the morbidity of pneumococcal 303 
disease; however, a clearer understanding of the dynamics of protein antigen immunity 304 
and pneumococcal carriage is required.  As with previous studies, we found that adult 305 
sera possessed antibodies to multiple antigens and to multiple variants of variable 306 
antigens, and antibody titers usually increased across participant age groups, with adults 307 
having higher overall mean anti-protein titers (7,14).  For PspA, StkP, and PhtD, a 308 
significant reduction in protein antibodies was observed between infants <6-months-old 309 
and children 6-24 months, likely resulting from the loss of maternally acquired antibodies 310 
and slower acquisition in infancy and toddlerhood than for other antigens.  While 311 
increasing natural immunity with age has been shown in previous studies of 312 
pneumococcal protein antigens (5,7,24), this is the first study to assess variant-specific 313 
antibodies and their effect on protection against homologous pneumococcal 314 
colonization.  We found increased carriage of pneumococci expressing var-I PspC 315 
among participants with lower anti-PspC var-I titers.  However, among all other protein 316 
antigens, including PspA, we found no difference in anti-protein antibody titers by 317 
subsequent colonization status with those variants.  Because our study was designed to 318 
focus on variant-specific protection by serum antibody against colonization with a 319 
particular antigenic variant, we did not assess antibody levels in individuals who were 320 
subsequently not colonized with pneumococcus, so we were unable to assess the 321 
absolute level of protection against colonization associated with particular levels of 322 
serum antibodies. Our results suggest that whatever protection these antibodies offer, it 323 
is modestly variant-specific for PspC and not measurably variant-specific for other 324 
antigens. 325 
PspC and PspA are structurally similar surface proteins (25) known for their 326 
interaction with the host immune system (26,27), involvement in host epithelial 327 
adherence (28), and high recombination rates (17,29).  Host immune evasion is often 328 
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invoked to explain the apparent increased recombination rates, sequence diversity and 329 
evidence of diversifying selection in pspA and pspC; however, there is no direct 330 
experimental evidence for this (30,31).  Studies so far have implicated anti-PspC in 331 
protection against colonization, while anti-PspA seems important for protection against 332 
invasive disease (14).  The growing interest in both PspC and PspA as vaccine 333 
candidates underscores the need for better understanding and characterization of the 334 
nature of anti-PspA and anti-PspC immunity.  335 
In this study, we investigated four variants of PspC, each representing one of the 336 
11 recognized PspC groups (12).  Our data suggest there may exist specificity against 337 
colonization based on exposure history, where colonization with a rare PspC variant 338 
leaves individuals susceptible to colonization with the most prevalent circulating strain.  339 
This observation is consistent with the concept of balancing selection in which the 340 
selective pressure of host immunity is sufficient to impact the frequency of specific PspC 341 
variants in the overall pneumococcal population.  In general, this hypothesis is supported 342 
by the observation of high rates of recombination in the PspC locus, which may provide 343 
a way for pneumococci to obtain a PspC variant with low population level host immunity.  344 
However, these underlying population dynamics require further exploration. 345 
In prior studies, anti-PspA titers in children reflected the PspA family to which 346 
they had been exposed (14), while adults often possessed high titers to both major 347 
families.  Among participants of this study, family 2 PspA variants were found in only 348 
27% of carriage isolates and mean anti-PspA family 2 variant titers were consistently 349 
lower among each age group.  However, we found that anti-PspA titers were not 350 
predictive of the subsequently carried strain. In the context of previous studies 351 
demonstrating the protective role of anti-PspA antibodies, it appears that the cross-352 
reactivity of antibodies may provide a broad level of protection from all PspA families. 353 
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The pneumococcal pilus, comprised of proteins RrgA, RrgB and RrgC, facilitates 354 
binding to lung epithelial cells and colonization (32) and has been explored as a potential 355 
vaccine candidate (33).  The pilus operon has been shown to recombine and be acted 356 
on by positive selection (34)  Immunization with pilus subunits has been shown to 357 
provide protection against systemic challenge with piliated pneumococcal strains (35).  358 
Previously estimated to be present in ~30% of pneumococci (36), pilus was present in 359 
only 11% of our studied strains.  We found that while anti-pilus antibody titers were 360 
significantly higher among adults compared with children, there was no difference in the 361 
proportion of carried strains that were piliated between these age groups.  Furthermore, 362 
anti-pilus titers were not predictive of either carriage of piliated strains or RrgB variant 363 
among carried piliated strains.  This was unexpected considering the high anti-RrgB 364 
titers in adults and the elevated RrgB var-III titers compared to variants I and II, which 365 
were less prevalent among piliated strains (Figure 2C).  The low prevalence of piliated 366 
strains in the pneumococcal isolates from this study or variations in pilus expression (37) 367 
may have reduced our ability to detect differential pneumococcal carriage according to 368 
antibody titers.   369 
While for the majority of protein antigen variants we failed to find any variant-370 
specific protective effect against carriage, it should be noted that immunity generated by 371 
naturally acquired antibodies is likely more complex than a simple variant-specific 372 
protective effect.  Several prior studies have suggested some degree of cross-reactivity 373 
between antibodies to one variant of a protein and pneumococci carrying another.  This 374 
could be consistent with subtle selective pressures imposed by modestly greater 375 
protection against homologous than heterologous variants, which may be hard to 376 
measure in a host population.  Furthermore immune responses against different proteins 377 
may have cumulative effects, such that the variant-specificity of antibodies to a particular 378 
protein would be obscured when considering the ability of these antibodies to protect 379 
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against a strain to which the individual may have many other effective antiprotein 380 
antibody responses. Indeed, challenge studies of protein-based vaccines in animal 381 
models have clearly shown that combination vaccines including 2-3 pneumococcal 382 
proteins are more efficacious for protection against invasive challenge (1,2).  This likely 383 
reflects the in vivo interaction of host immunity with multiple pneumococcal antigens; 384 
however, this interaction is difficult to investigate.  We observed a correlation of anti-385 
protein titers among several antigen variants, suggesting that individuals likely possess a 386 
repertoire of antibodies to a specific set of protein antigen variants. 387 
Certain limitations should be considered when interpreting our results.  We 388 
selected genetic variants of protein antigens based on extant literature and phylogenetic 389 
analysis, identifying one strain from each monophyletic clade to represent a putatively 390 
antigenically distinct variant.  However, each of these protein variants possesses several 391 
distinct epitopes, each likely generating a different antibody response.  It is conceivable 392 
that antibodies against one protein antigen are in fact a mixture of antibodies of varying 393 
specificity, complicating the characterization of the overall response against one antigen.  394 
This is certainly a confounding factor in our analysis and future studies should assess 395 
pneumococcal anti-protein antibody repertoires and functionally characterize distinct 396 
protein antigen variants (e.g. PspC) to determine the nature of the antibody response 397 
they elicit and further our understanding of protection while informing vaccine 398 
development.  Secondly, the exposure histories of participants are unknown, and 399 
participants were seemingly less likely to be exposed to rare protein variants in the 400 
pneumococcal population.  Overall, using a large sample pneumococcal strains and sera 401 
from those who carried these strains we found only modest evidence for variant-402 
specificity of protection against pneumococcal carriage.  403 
 404 
 405 
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Figures and Tables 
 
Table 1. Pneumococcal serotypes by age group and ordered by prevalence. 
 Age Group   
Serotyp
e <1 1-4 y 5-17y 18y+ Total 
% of 
Total 
19A 5 2.07% 7 2.89% 0 0.00% 10 4.13% 22 9.07% 
22A 4 1.65% 10 4.13% 4 1.65% 3 1.24% 21 8.67% 
35B 6 2.48% 6 2.48% 3 1.24% 6 2.48% 21 8.67% 
23B 2 0.83% 8 3.31% 3 1.24% 4 1.65% 17 7.02% 
15A 1 0.41% 7 2.89% 2 0.83% 3 1.24% 13 5.37% 
34 0 0.00% 6 2.48% 1 0.41% 6 2.48% 13 5.36% 
6B 1 0.41% 4 1.65% 2 0.83% 5 2.07% 12 4.95% 
11D 2 0.83% 3 1.24% 4 1.65% 2 0.83% 11 4.54% 
23A 1 0.41% 4 1.65% 1 0.41% 4 1.65% 10 4.13% 
31 2 0.83% 3 1.24% 3 1.24% 0 0.00% 8 3.31% 
16F 0 0.00% 2 0.83% 4 1.65% 2 0.83% 8 3.30% 
17F 2 0.83% 0 0.00% 2 0.83% 4 1.65% 8 3.30% 
37 2 0.83% 0 0.00% 1 0.41% 4 1.65% 7 2.89% 
6A 0 0.00% 3 1.24% 3 1.24% 0 0.00% 6 2.48% 
21 0 0.00% 3 1.24% 2 0.83% 1 0.41% 6 2.48% 
35F 2 0.83% 2 0.83% 0 0.00% 2 0.83% 6 2.48% 
7B 1 0.41% 1 0.41% 0 0.00% 4 1.65% 6 2.47% 
10A 0 0.00% 3 1.24% 1 0.41% 1 0.41% 5 2.06% 
15C 1 0.41% 1 0.41% 0 0.00% 3 1.24% 5 2.06% 
3 0 0.00% 1 0.41% 2 0.83% 1 0.41% 4 1.65% 
35A 0 0.00% 3 1.24% 0 0.00% 1 0.41% 4 1.65% 
NT 2 0.83% 1 0.41% 0 0.00% 1 0.41% 4 1.65% 
10B 0 0.00% 1 0.41% 2 0.83% 0 0.00% 3 1.24% 
7C 0 0.00% 1 0.41% 1 0.41% 1 0.41% 3 1.24% 
1 0 0.00% 1 0.41% 0 0.00% 2 0.83% 3 1.24% 
19F 1 0.41% 0 0.00% 1 0.41% 0 0.00% 2 0.83% 
22F 0 0.00% 1 0.41% 1 0.41% 0 0.00% 2 0.83% 
38 0 0.00% 1 0.41% 1 0.41% 0 0.00% 2 0.83% 
12A 0 0.00% 1 0.41% 0 0.00% 1 0.41% 2 0.82% 
12B 0 0.00% 1 0.41% 0 0.00% 1 0.41% 2 0.82% 
15B 0 0.00% 0 0.00% 1 0.41% 0 0.00% 1 0.41% 
5 0 0.00% 0 0.00% 1 0.41% 0 0.00% 1 0.41% 
7A 1 0.41% 0 0.00% 0 0.00% 0 0.00% 1 0.41% 
8 0 0.00% 1 0.41% 0 0.00% 0 0.00% 1 0.41% 
9A 0 0.00% 1 0.41% 0 0.00% 0 0.00% 1 0.41% 
10F 0 0.00% 0 0.00% 0 0.00% 1 0.41% 1 0.41% 
Total 36 14.9% 87 36.0% 46.0 19% 73 30.2% 242 100.00% 
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Table 2. Protein antigens and variant frequencies identified through genomic analysis of pneumococcal carriage isolates.  The 
antigen name and function are listed with the number of variants tested.  Variants with measured titers are specified with an asterisk.   
Polymorphic 
Antigen   Variant Strain Accesion/Gene Count Freq P-Distance 
I. PspC 
Pneumococcal surface 
protein C Var-I* ND6053 ERR129207 203 83.9% 0.025 (0.025-0.025) 
   Var-II* CH2016 ERR129074 31 12.8% 0.007 (0.006-0.008) 
   Var-III* BR1086 ERR129054 3 1.2% 0.005 (0.001-0.009) 
   Var-IV* MD5090 ERR129180 1 0.4% - 
II. PspA 
Pneumococcal surface 
protein A Family 1* D39 SPD_0126 166 68.6% 
0.200 (0.199-0.201) 
   Family 2* TIGR4 SP_0117 69 28.5% 
   Family 3 BG6380 AF071823 4 1.7% 
III.  RrgA 
RrgA pilus subunit, 
adhesin Var-I* TIGR4 SP_0462 24 88.9% 0.032 (0.027-0.037) 
   Var-II 670-6B SP670_0540 3 11.1% 
IV. RrgB 
RrgB pilus subunit, 
backbone Var-I* 670-6B SP670_0541 4 13.8% 
0.216 (0.199-0.233)    Var-II* TIGR4 SP_0463 11 37.9% 
   Var-III* 23F_Taiwan_15 
EF560629: 5159-
7123 14 48.3% 
V. NanA Neuraminidase Var-I* D39 SPD_1504 7 3.0% 
0.042 (0.041-0.042) 
   Var-II INV200 
SPNINV200_1514
0 75 32.2% 
   Var-III ATCC 700669 SPN23F16920 151 64.8% 
VI. SP0609 
Amino acid ABC 
transporter Var-I* TIGR4 SPD_0530 161 66.8% 0.015 (0.015-0.015) 
   Var-II ATCC 700669 SPN23F05490 80 33.2% 
VII. SP2194 
ATP-dependent Clp 
protease Var-I Taiwan19F-14 SPT_2213 222 91.7% 0.010 (0.010-0.010) 
   Var-II* TIGR4 SP_2194 20 8.3% 
VIII. PhtD 
Pneumococcal histidine 
triad D Var-I ATCC 700669 SPN23F09290 168 70.9% 0.062 (0.060-0.064) 
   Var-II* D39 SPD_0889 69 29.1% 
IX. StkP 
Serine threonine kinase 
protein Var-I D39 SPD_1542 181 74.8% 
0.007 (0.007-0.007) 
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   Var-II* TIGR4 SP_1732 61 25.2% 
X. StrH 
Beta-N-
acetylhexosaminidase Var-I* D39 SPD_0063 101 42.1% 0.007 (0.007-0.007) 
   Var-II TIGR4 SP_0057 139 57.9% 
XI. Ply Pneumolysin Var-I* D39 SPD_1726 29 12.0% 
0.003 (0.003-0.003) 
   Var-II* TIGR4 SP_1923 213 88.0% 
Conserved 
Antigen   Variant Strain Accession/Gene - -   
XII. LysM 
LysM domain-
containing protein Var-I* TIGR4 SP_0107 - - 0.004 (0.003-0.004) 
XIII. LytB 
Endo-beta-N-
acetylglucosaminidase Var-I* D39 SPD_0853 - - 0.008 (0.008-0.008) 
XIV. LytC Lysozyme (C-ter) Var-I* D39 SPD_1403 - - 0.005 (0.005-0.005) 
XV. PcpA Choline binding protein Var-I* D39 SPD_1965 - - 0.003 (0.003-0.003) 
XVI. PcsB 
Secreted 45 kDa 
protein Var-I* TIGR4 SP_2216 - - 0.006 (0.006-0.007) 
XVII. PhtE 
Truncated histidine 
triad protein Var-I* D39 SPD_0890 - - 0.008 (0.008-0.008) 
XVIII. PiaA 
Part of iron uptake 
ABC transporter Var-I* D39 SPD_0915 - - 0.002 (0.002-0.002 
XIX. PiuA 
Part of iron uptake 
ABC transporter Var-I* D39 SPD_1652 - - 0.005 (0.005-0.005) 
XX. PsaA 
Pneumococcal surface 
adhesin A Var-I* TIGR4 SP_1650 - - 0.003 (0.002-0.003) 
XXI. SP2027 
Conserved 
hypothetical protein Var-I* TIGR4 SP_2027 - - 0.005 (0.005-0.006) 
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Figure 1. Pearson correlations of log10 antibody titers for 28 protein antigens clustered 
heuristically by correlation value.  Correlations between normalized antibody titers of 
protein antigens were clustered using heuristic methods.  Protein antigens including 
multiple variants of the same antigen are labeled on the x- and y- axes, and the heatmap 
displays the correlation values between antigens.  The dendrogram on the left 
represents the results of the heuristic clustering of correlated antibody titers.  Significant 
correlation between variants of the same antigen was observed as well as high 
correlation among several antigens, which likely exist on the same genomic background. 
 
Figure 2.  Protein antibodies titers by age for variants of PspC, PspA, pilus, and ply.  
Antibody levels were measured using direct binding electrochemiluminescence-based 
multiplex assay are expressed as a titer relative to the amount in a reference serum.  
Structural variants of polymorphic proteins were measured individually and were 
compared among participant age groups.  A.) Variant-specific anti-PspC antibodies to 
Var-I (ND6053), Var-II (CH2016), Var-III (BR1086), and Var-IV (MD5090).  B.) Variant-
specific anti-PspA antibodies to Family 1 and Family 2.  C.) Anti-pilus antibodies to 
RrgA-I (TIGR4) and RrgB pilus variants RrgB-I (670-6B), RrgB-II (Taiwan 23F), and 
RrgB-III (TIGR4).  D.) Variant-specific anti-pneumolysin (ply) antibodies to variants I and 
II. 
 
Figure 3. Protein antibody titers among participants carrying pneumococcal strains with 
specific polymorphic protein-antigen variants.  Serum was collected from participants at 
enrollment, and nasopharyngeal swabs for pneumococcal carriage detection were 
collected at least 30 days after serum collection.  The protein antigen variant in each 
pneumococcal isolate was determined using genomic data.  Antibody levels were 
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measured using direct binding electrochemiluminescence-based multiplex assay are 
expressed as a titer relative to the amount in a reference serum.  Structural variants of 
polymorphic proteins were measured individually.  The y-axis represents the variant-
specific antibody titers, and the carriage isolate protein antigen variant is specified on the 
x-axis with labels colored to match the corresponding titers.  If susceptibility to a strain 
possessing a specific variant were observed, the respective antibody titer would be the 
lowest among all other titers.  A) Anti-PspC titers vs. carriage isolate PspC variants I-IV 
and non-typable.  B) Anti-PspC titers vs. carriage isolate PspC var-I and combined var-
II-IV.  C) Anti-PspA Family 1 and Family 2 titers vs. carriage isolate PspA variants 
Families 1, 2, 3, and unknown.  D) Anti-pilus titers vs. carriage isolate RrgB variants I-III 
and not present. 
  
